Biotech

Lexaria Bioscience Corp (LEXX) is making headlines again this week. In a studyconducted by a leading independent testing facility, DehydraTECH™ 2.0 nicotine pouches easily outperformed generic nicotine benzoate pouches, hitting peak delivery rates within eight minutes, and then again at thirty minutes. The generic pouches hit peak at forty-five minutes.  

 

It's a significant disparity when comparing two similar products, but Lexaria already knows their technology works. DehydraTECH™ absorption has been extensively tested with cannabinoids since 2018. Lexaria's DehydraTECH™ CBD is currently in human clinical trials as an anti-hypertensive drug. The results there have been positive at every phase. 

 

According to CEO Chris Bunka, "DehydraTECH™ Nicotine Pouches can deliver nicotine into the bloodstream at a rate that is ten to twenty times faster than the controls in this latest study. Our goal is to render pulmonary administration practices like smoking and vaping obsolete. Performance gains of this magnitude could make that possible." 

 

Nicotine Absorption Rates Have Hampered the Nicotine Pouch Market

 

Cigarette smoking kills eight million people every year. It's also highly addictive, so smokers are reluctant to give it up for a substitute that doesn't deliver the desired dose of nicotine. That's what's been slowing the growth of the nicotine pouch market. Existing products don't deliver enough nicotine into the bloodstream to satisfy the cravings of smokers. 

 

Vaping is not the answer. According to a study published by Harvard Medical School, "Nearly 200 e-cigarette users in twenty-two states have developed serious lung disease." It's a small data set and the link cannot be proven, but medical professionals believe it's due to chemical irritants or allergic reactions to substances in the inhaled vapors. 

 

Nicotine pouches, on the other hand, have passed the test of time. The FDA gave authorization in 2019 for nicotine pouch manufacturers to display reduced risk claims on their packaging. The wording of these claims is, "Puts you at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." That's in comparison to cigarettes.

 

Unfortunately, if smokers quit based on health hazards alone, there wouldn't be a need for nicotine substitution. Lexaria believes the answer is to provide a nicotine pouch that delivers higher doses of nicotine to the bloodstream faster. DehydraTECH™ Nicotine Pouches accomplish that. They are the first oral deliverable that can truly satisfy the smoker's craving.

 

Global Nicotine Products are an $818 Billion Market

 

DehydraTECH™ Nicotine Pouches deliver a maximum dose of nicotine in eight minutes. The global nicotine market is estimated at $818 billion in annual global sales. That includes cigarettes, cigars, nicotine gum, lozenges, patches, and nicotine pouches, which were estimated at $2.3 billion in sales last year. DehydraTECH Nicotine Pouches are not on the market yet.    

 

That's a small percentage of the overall nicotine market, but sales of nicotine pouches are expected to grow to $22 billion by 2027, and that's the low end of the scale. A potent oral substitute for smokers could make the number go up exponentially. With DehydraTECH™ Nicotine Pouches, Lexaria is positioned to make that happen.       

 

Disclaimer
This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its client's securities. See www.pcgadvisory.com/disclosures.

PCG Digital
info@pcgadvisory.com
646-863-6341

News Provided by NewMediaWire via QuoteMedia

European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy® for the Treatment of HIV in Pediatric Populations

EC Authorizes a Low-Dose Tablet for HIV Treatment in Virologically Suppressed Children at Least Two Years of Age and Weighing at Least 14 kg, Helping to Address a Critical Unmet Need –

– Biktarvy Provides an Effective Therapy Choice for a Diverse Range of People Living with HIV, including Children with Limited Treatment Options –

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Collaboration will leverage Envisagenics' SpliceCore® AI platform for accelerated discovery and development of oncology therapeutic candidates

Envisagenics an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY). The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Komo Reports Fiscal Year 2022 Financial Results

Komo Reports Fiscal Year 2022 Financial Results

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ("Komo"), a premium plant-based food company, today reports financial results for the year ended July 31, 2022.

"We began our fiscal year as a new brand with a mission to make plant-based meals a staple on every dinner table by sharing our love for feel-good food that connects the people to the planet. Thanks to the strength of our team and the love of Komo products, we were successful in achieving sales growth of 935 percent over last year," says Komo founder and CEO William White. "The consistently strong retail sales of our products have allowed us to demonstrate to large retail chains that our products sell well and have repeat customers. We recently completed a national listing with Loblaws and we are in discussions with several other large national chains. As a result, we are anticipating continued significant revenue increases in 2023."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Grant of Stock Options

The Gummy Project Announces Grant of Stock Options

The Gummy Project Inc. (CSE: GUMY) (FSE: 0OS0) (OTCQB: GUMYD) ("GUMY" or the "Company") announces that it has issued a total of 2,300,000 stock options pursuant to its incentive stock option plan ("Plan") to consultants which vest on the grant date. Each option entitles the holder to subscribe for one common share of the Company for $0.06 for a period of 5 years, subject to the terms of the Plan. Over the past quarter, 1,664,800 options have lapsed or been cancelled.

About The Gummy Project

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday Dec. 5, 2022. David M. Reese M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team, will discuss the Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.

The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer

Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy Arm in First-Line NSCLC Patients –

Data will be Presented on December 20, 2022 at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×